A clinical-stage biotechnology company developing a first-in-class small-molecule therapeutic for acute neurological injuries has just secured new capital to advance its lead candidate through mid-stage development. On September 30, 2026, Connecticut-based Astrocyte Pharmaceuticals announced the completion of a $9.5 million Series B financing round to support Phase 2 development of AST-004, its proprietary small-molecule cerebroprotectant. The round was led by DeepWork Capital, with participation from MintPharma Capital, Dynagrow Capital, Angel Star Ventures, and existing investors, bringing total capital invested in the company to approximately $40 million including grants to date.
STARFAST Trial Completes Enrollment
The financing comes as Astrocyte’s first Phase 2 study of AST-004 has completed patient enrollment. The STARFAST trial — formally known as the Study of Traumatic Brain Injury/Concussions in Australian-Rules Footballers receiving AST-004 — is a double-blinded, placebo-controlled study evaluating the safety and clinical efficacy signals of AST-004 infusion in athletes diagnosed with sports-related concussion. Male and female athletes receive either intravenous AST-004 or placebo within six hours of injury. Topline results from the trial are expected in winter 2026.
“The completion of enrollment in our STARFAST trial and this new financing represent major milestones for Astrocyte,” said Dr. William S. Korinek, President and CEO of Astrocyte Pharmaceuticals. “With these resources, we are well positioned to advance AST-004 through Phase 2 development and toward the patients who need it most.”
How AST-004 Works
AST-004 is a small-molecule adenosine A1R/A3R receptor agonist designed to enhance mitochondrial energy metabolism in astrocytes — the glial cells that support neuronal function and recovery after injury. By activating adenosine A1 and A3 receptors, the compound stimulates intrinsic cerebroprotective mechanisms, including protection against edema, glutamate excitotoxicity, and oxidative stress. The drug candidate is currently in Phase 2 clinical development for sports-related concussion, with potential applications extending to acute ischemic stroke, traumatic brain injury, and other neurological conditions.
Why This Matters for the Chemical Supply Chain
Unlike large pharmaceutical companies investing in manufacturing facilities, Astrocyte represents a different segment of the drug development ecosystem — the clinical-stage biotech. For suppliers of pharmaceutical intermediates and specialty chemicals, this distinction matters. Companies at Astrocyte’s stage are typically focused on clinical execution rather than commercial-scale procurement, but their progression through Phase 2 triggers specific upstream needs: process optimization, impurity standards, reference materials, and supplementary batch synthesis as formulations evolve.
For the chemical supply chain, clinical-stage biotechs represent a segment with distinct needs and timelines. Phase 2 advancement often generates demand for analytical standards, impurity references, and small-scale custom synthesis to support process development and regulatory filings. As candidates progress toward later stages, requirements shift toward scale-up support and supply chain qualification.
What This Means for XinChem Customers
XinChem’s core capabilities in small-molecule intermediates and gram-to-kilogram custom synthesis align with the needs of clinical-stage drug developers navigating this progression. Whether supplying impurity standards for analytical method development, providing custom-synthesized reference compounds, or supporting process optimization with specialty intermediates, XinChem remains committed to serving customers across the drug development continuum.
For U.S. biotech customers evaluating supply partners, the key considerations are consistent: responsive communication, reliable documentation, and the flexibility to support evolving requirements from early development through clinical stages. XinChem invites inquiries for specific intermediate requirements and custom synthesis projects.
Contact us today to start your partnership with XinChem!
Website: www.xinchem.com
Email: sales1@xinchem.com
WhatsApp: +86 18049800532
Post time: Oct-07-2026